This article reviews the metabolic pharmacokinetic drug-drug interactions with the systemic
antifungal agents: the azoles ketoconazole, miconazole, itraconazole and fluconazole, the …

1. The molecular and functional characterization of transport proteins is emerging rapidly
and significant numbers of drugs have been shown to be substrates or inhibitors. The …

Background—Although quinidine is known to elevate plasma digoxin concentrations, the
mechanism underlying this interaction is not fully understood. Digoxin is not extensively …

Grapefruit juice can alter oral drug pharmacokinetics by different mechanisms. Irreversible
inactivation of intestinal cytochrome P450 (CYP) 3A4 is produced by commercial grapefruit …

Patients undergoing treatment with immunosuppressant drugs following solid organ or
hematopoietic stem cell transplantation are at particular risk for development of serious …

This is a comprehensive, clinically oriented review of the four commercially available
triazoles: fluconazole, itraconazole, voriconazole, and posaconazole. Emphasis is placed in …

Objective Recent data indicated that disposition of oral digoxin is modulated by intestinal P‐
glycoprotein. The cardioselective β‐blocker talinolol has been described to be secreted by …

Itraconazole is a new triazole compound with a broad spectrum of activity against a number
of fungal pathogens, including Aspergillus species. The drug is being used increasingly as …

Itraconazole strongly interacts with some drugs metabolized by cytochrome P450 3A4, for
example, felodipine and lovastatin, by inhibiting their metabolism. A concomitant use of …

Objective Pharmacy clinical decision-support (CDS) software that contains drug–drug
interaction (DDI) information may augment pharmacists' ability to detect clinically significant …